Transition of care from adolescence to early adulthood in severe asthmatic patients treated with omalizumab in real life

Camille Taillé; Marc Humbert; Arnaud Bourdin; Céline Thonnelier; Audrey Lajoinie; Jules Chassetuillier; Mathieu Molimard; Antoine Deschildre

doi:10.1183/23120541.00976-2023

Transition of care from adolescence to early adulthood in severe asthmatic patients treated with omalizumab in real life

ERJ Open Res. 2024 Jul 8;10(4):00976-2023. doi: 10.1183/23120541.00976-2023. eCollection 2024 Jul.

Authors

Camille Taillé¹, Marc Humbert², Arnaud Bourdin³, Céline Thonnelier⁴, Audrey Lajoinie⁵, Jules Chassetuillier⁵, Mathieu Molimard⁶, Antoine Deschildre⁷

Affiliations

¹ Service de pneumologie et Centre de Référence des Maladies Pulmonaires rares, Hôpital Bichat, Groupe Hospitalier Universitaire AP-HP Nord; UMR 1152, Université Paris Cité, Paris, France.
² Université Paris-Saclay, INSERM, Assistance Publique Hôpitaux de Paris (AP-HP), Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
³ University of Montpellier, INSERM U1046, CNRS UMR 9214, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Hôpital Arnaud-de-Villeneuve, Montpellier, France.
⁴ Novartis, Rueil Malmaison, France.
⁵ RCTs, Lyon, France.
⁶ Service de Pharmacologie Médicale, CHU de Bordeaux, Université de Bordeaux, INSERM CR1219, Bordeaux, France.
⁷ Université de Lille, CHU Lille, Pediatric Pulmonology and Allergy Department, Hôpital Jeanne de Flandre, Lille, France.

Abstract

Half of severely asthmatic adolescents treated with omalizumab transitioning to adulthood discontinue the treatment, suggesting insufficient asthma control. However, most of the other half have low rates of HCRU markers, their asthma being under control. https://bit.ly/49ixpxt.